Table 1 |
||
|
Baseline patient characteristics by vaccination status |
||
|
Vaccination status |
||
|
Baseline characteristics, n (%) |
Vaccinated n = 551 |
Unvaccinated n = 43,564 |
|
|
||
|
Age groups (years) |
||
|
50 to 59 |
202 (36.7) |
30,156 (69.2) |
|
60 to 64 |
275 (49.9) |
9,573 (22.0) |
|
65 and older |
74 (13.4) |
3,835 (8.8) |
|
Women |
352 (63.9) |
27,091 (62.2) |
|
Inflammatory/Autoimmune disease |
||
|
RA |
206 (37.4) |
19,120 (43.9) |
|
Psoriatic arthritis |
11 (2.0) |
856 (2.0) |
|
Psoriasis |
146 (26.5) |
10,566 (24.3) |
|
Inflammatory bowel diseases |
136 (24.7) |
8,503 (19.5) |
|
Ankylosing spondylitis |
8 (1.5) |
625 (1.4) |
|
Multiple diseases |
44 (8.0) |
3,894 (8.9) |
|
Medicationsa |
||
|
TNF antagonists user |
27 (4.9) |
4,186 (9.6) |
|
Other biologics user |
0 (0) |
198 (0.5) |
|
Conventional DMARDs user |
92 (16.7) |
9,312 (21.4) |
|
Oral glucocorticoidsb |
||
|
None |
456 (82.8) |
34,267 (78.7) |
|
Low |
86 (15.6) |
8,041 (18.5) |
|
Medium |
7 (1.3) |
902 (2.1) |
|
High |
2 (0.4) |
354 (0.8) |
|
Charlson comorbidity index |
||
|
0 |
287 (52.1) |
19,971 (45.8) |
|
1 |
181 (32.9) |
16,565 (38.0) |
|
≥ 2 |
83 (15.1) |
7,028 (16.1) |
|
Inpatient hospitalization |
||
|
No |
466 (84.6) |
36,158 (83.0) |
|
Yes |
45 (15.4) |
7,406 (17.0) |
|
Number of outpatient physician visits |
||
|
0-2 |
83 (15.1) |
8,705 (20.0) |
|
3-5 |
227 (41.2) |
16,843 (38.7) |
|
6-10 |
185 (33.6) |
13,376 (30.7) |
|
11 and more |
54 (9.8) |
4,642 (10.7) |
|
|
||
|
DMARDS, Disease-modifying antirheumatic drugs; RA, rheumatoid arthritis; TNF, tumor necrosis factor. aMeasured in the 6-month baseline period before the start of observation bCumulative average daily prednisone-equivalent glucocorticoid dose in the past 183 days: none, low (< 10 mg/day), medium (10-20 mg/day), and high (> 20 mg/day). |
||
|
Zhang et al. Arthritis Research & Therapy 2011 13:R174 doi:10.1186/ar3497 |
||
